Raymond James Financial
MAIA icon

Raymond James Financial’s MAIA Biotechnology MAIA Stock Holding History

Raymond James Financial’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$180 – 5982
2025
Q2 		$180 Buy
+100
New +$179 ﹤0.01% 6795

Other funds holding MAIA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CAG
Centerpoint Advisory Group Overland Park, Kansas $158M AUM 26.37% 1-Year Est. Return

Raymond James Financial's MAIA Position: Q3 2025 in Review

Raymond James Financial sold out of MAIA Biotechnology (MAIA) in Q3 2025, closing a stake of 100 shares — an estimated $180 sold.

Raymond James Financial first reported a position in MAIA in Q2 2025 and held it in 1 quarter. The position peaked at $180 in Q2 2025. 19 funds tracked by Wall St. Rank hold MAIA as of Q3 2025.

  • Raymond James Financial reported no remaining MAIA Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 100 MAIA Biotechnology shares in Q3 2025, an estimated $180.
  • Raymond James Financial first reported a position in MAIA Biotechnology in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's MAIA Biotechnology position peaked at $180 in Q2 2025.
  • 19 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.